Loading
Aquestive Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 Jun 2022.
Aquestive Therapeutics, Inc.: what insiders have been doing
Aquestive Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Aquestive Therapeutics, Inc. logged 33 filings by 13 insiders.
There is no open-market purchase to report; the filings show 8 sales worth €418k by 3 insiders. The totals do not cover 2 filings with an undisclosed amount. Biggest ticket of the year: €104k, sold by Barber Daniel and made public on 16 September 2026 (0.020% of market cap).
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 33 filings here. Over the whole record (from 2021), the tally stands at 5 purchases and 17 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 44.5 m USD and net income at -83.8 m USD.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
94
Thresholds
n/a
Buy Volume
€141,522
5 ops. · all time
Sell Volume
€2M
17 ops. · all time
Who traded when
BuySaleDaniel Barber8 sales
Peter E. Boyd3 sales
Cassie Jung1 sale
Julie Krop1 sale
Kraus Carl N1 sale
Sherry Korczynski1 sale
Since the insiders bought
- +197.1%Entry US$0.73 · Close at T+365 US$2.16
- +153.7%Entry US$0.82 · Close at T+365 US$2.08
- +153.7%Entry US$0.82 · Close at T+365 US$2.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.67
Analyst consensus
9 analysts1.22/5
US$6.00Target US$9.33(+100%)US$11.00
Income statement
RevenueUS$44.5M
Gross profitUS$26M58% margin
EBITDA-US$66.1M-148% margin
Net income-US$83.8M-144.6% margin
Valuation
PER (forward)-8.2x
Beta1.49
Balance sheet & cash
Market capUS$586.1M
Total debtUS$42.5M
Free Cash Flow-US$53M
Profitability & ownership
ROA-29.2%
% insiders10.8%
% institutions58.4%
Last declaration on 16 October 2026
Declarations94 total
25,000 shares@ US$4.224Common StockSEC:0001214659-26-012986:0
25,000 shares@ US$4.81950.020% mcap7.8% of flowCommon StockSEC:0001214659-26-011731:0
50,000 shares@ US$4.880.041% mcap43.9% of flowCommonSEC144:0001950047-26-009530
8,750 shares@ US$2.650.0038% mcap25.7% of flowCommon StockSEC:0001214659-26-011596:0
8,750 shares@ US$5.220.0076% mcap50.6% of flowCommon StockSEC:0001214659-26-011596:1
2,293 shares@ US$0.960.0004% mcap0.8% of flowCommon StockSEC:0001214659-26-011541:0
8,750 shares@ US$5.210.0076% mcap100.0% of flowCommonSEC144:0001950047-26-009243
91,743 shares@ US$0.960.015% mcap5.7% of flowCommon StockSEC:0001214659-26-011539:0
4,587 shares@ US$0.960.0007% mcap1.6% of flowCommon StockSEC:0001214659-26-011475:0
25,000 shares@ US$4.28670.018% mcap6.9% of flowCommon StockSEC:0001214659-26-010516:0
25,000 shares@ US$4.250.018% mcap19.1% of flowCommonSEC144:0001950047-26-008250
2,714 shares@ US$4.250.0019% mcap12.9% of flowCommon StockSEC:0001214659-26-010474:0
20,369 shares@ US$4.00160.014% mcap5.3% of flowCommon StockSEC:0001214659-26-008663:1
4,631 shares@ US$4.03440.0032% mcap1.2% of flowCommon StockSEC:0001214659-26-008663:0
25,000 shares@ US$4.040.017% mcap18.3% of flowCommonSEC144:0001950047-26-007131
25,000 sharesCommon StockSEC:0001214659-26-007677:0
25,000 sharesCommon StockSEC:0001214659-26-007677:1
25,000 shares@ US$4.720.022% mcap100.0% of flowCommonSEC144:0001950047-26-006421
25,000 sharesCommon StockSEC:0001214659-26-007511:0
25,000 shares@ US$4.170.019% mcap18.7% of flowCommonSEC144:0001950047-26-006103
2,714 sharesCommon StockSEC:0001214659-26-007262:0
80,000 shares0Common StockSEC:0001214659-26-003147:0
95,000 shares0Common StockSEC:0001214659-26-003143:0
50,000 shares0Common StockSEC:0001214659-26-003140:0
262,000 shares0Common StockSEC:0001214659-26-003146:0
25 of 94 declarations
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States. Founded in 2005 as MonoSol Rx and later renamed Aquestive Therapeutics, the company has built its identity around PharmFilm®, a proprietary oral and sublingual thin-film drug delivery platform designed to deliver complex molecules without needles or conventional invasive devices. For investors in French-speaking Europe, Aquestive should be viewed less as a broad large-cap pharma company and more as a specialized drug-delivery and formulation platform business with selective proprietary assets.
The company’s operating model rests on three pillars. First, it commercializes licensed products and generates revenue from products marketed through partners. Second, it develops proprietary late-stage candidates that may create higher upside if approved and launched successfully. Third, it collaborates with pharmaceutical companies to reformulate established molecules into differentiated dosage forms using its technology. Aquestive has already secured multiple FDA approvals over time, including Zuplenz® (ondansetron), Suboxone® film, Sympazan® and Exservan®, demonstrating both regulatory execution and manufacturing know-how. Its production facilities are located in Portage, Indiana, while its corporate headquarters and primary research laboratories are in Warren, New Jersey.
Read moreShow less
From a competitive standpoint, Aquestive occupies a niche position in oral and sublingual formulations where ease of administration, rapid onset, patient convenience and adherence can matter materially. That positioning gives it differentiation in therapeutic areas such as severe allergies, central nervous system disorders and other specialty indications. However, the company remains relatively small, and its market narrative is driven more by product pipeline milestones than by a broad commercial footprint.
The key asset for investors is Anaphylm™, a no-needle, no-device epinephrine sublingual film intended for severe allergic reactions, including anaphylaxis. In 2025, Aquestive disclosed FDA acceptance of the NDA and a PDUFA target action date of January 31, 2026. Following a subsequent regulatory setback announced in 2026, the company said it expects to resubmit the NDA in Q3 2026, assuming completion of the required HF and PK studies. Another important development program is AQST-108, a topical epinephrine prodrug gel being evaluated for alopecia areata and other dermatology opportunities; the company opened an IND with the FDA in late 2025.
Geographically, Aquestive remains primarily U.S.-based in terms of operations, manufacturing and headquarters, even though it may leverage licensing and collaboration arrangements beyond the United States. Recent headlines include an August 2025 equity financing to support potential commercialization of Anaphylm, plus continued clinical and regulatory progress across its pipeline. Overall, Aquestive is best characterized as a catalyst-driven specialty pharma name, where valuation is highly sensitive to FDA decisions, clinical data and commercial execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
